|
1.
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signaling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Rowinsky EK: The erbB family: targets for
therapeutic development against cancer and therapeutic strategies
using monoclonal antibodies and tyrosine kinase inhibitors. Annu
Rev Med. 55:433–457. 2004. View Article : Google Scholar
|
|
3.
|
Wieduwilt MJ and Moasser MM: The epidermal
growth factor receptor family: biology driving targeted
therapeutics. Cell Mol Life Sci. 65:1566–1584. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Laurent-Puig P, Lievre A and Blons H:
Mutations and response to epidermal growth factor receptor
inhibitors. Clin Cancer Res. 15:1133–1139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Peyssonnaux C and Eychene A: The
Raf/MEK/ERK pathway: new concepts of activation. Biol Cell.
93:53–62. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Davies H, Bignell GR, Cox C, et al:
Mutations of the BRAF gene in human cancer. Nature. 417:949–954.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Brose MS, Voipe P, Feldman M, et al: BRAF
and RAS mutations in human lung cancer and melanoma. Cancer Res.
62:6997–7000. 2002.PubMed/NCBI
|
|
8.
|
Naoki K, Chen T-H, Richards WG, Sugarbaker
DJ and Meyerson M: Missense mutations of the BRAF gene in human
lung adenocarcinoma. Cancer Res. 62:7001–7003. 2002.PubMed/NCBI
|
|
9.
|
Hoque MO, Brait M, Rosenbaum E, et al:
Genetic and epigenetic analysis of erbB signaling pathway genes in
lung cancer. J Thorac Oncol. 5:1887–1893. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Paik PK, Arcila ME, Fara M, et al:
Clinical characteristics of patients with lung adenocarcinomas
harboring Braf mutations. J Clin Oncol. 29:2046–2051. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Lee YS, Kim MJ, Jin G, et al: Somatic
mutations in epidermal growth factor receptor signaling pathway
genes in non-small cell lung cancers. J Thorac Oncol. 5:1734–1740.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Sasaki H, Shimizu S, Endo K, et al: EGFR
and erbB2 mutation status in Japanese lung cancer patients. Int J
Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. New Eng J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Pao W, Miller V, Zakowski M, et al: EGF
receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and elrotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
|
|
16.
|
Sasaki H, Endo H, Konishi A, et al: EGFR
mutation status in Japanese lung cancer patients: genotyping
analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Mok TS, Wu Y-L, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
New Eng J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer habouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomized phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
19.
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. New Eng J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Stephens P, Hunter C, Bignell G, et al:
Intragenic erbB2 kinase mutations in tumors. Nature. 431:525–526.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Shigematsu H, Takahashi T, Nomura M, et
al: Somatic mutations of the HER2 kinase domain in lung
adenocarcinomas. Cancer Res. 65:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Tomizawa K, Suda K, Onozato R, et al:
Prognostic and predictive implications of HER2/ERBB2/neu gene
mutations in lung cancers. Lung Cancer. 74:139–144. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Sasaki H, Kawano O, Endo K, et al:
Uncommon V599E Braf mutations in Japanese patients with lung
cancer. J Surg Res. 133:203–206. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Sasaki H, Hikosaka Y, Kawano O, Moriyama
S, Yano M and Fujii Y: Evaluation of Kras mutation and copy number
gain in non-small cell lung cancer. J Thorac Oncol. 6:15–20. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Ikenoue T, Hikiba Y, Kanai F, et al:
Functional analysis of mutations within the kinase activation
segment of B-Raf in human colorectal tumors. Cancer Res.
63:8132–8137. 2003.PubMed/NCBI
|
|
26.
|
Ji H, Wang Z, Perera SA, et al: Mutations
in Braf and Kras converse on activation of the mitogen-activated
protein kinase pathway in lung cancer mouse models. Cancer Res.
67:4933–4939. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Welbrock C and Huristone A: BRAF as
therapeutic target in melanoma. Biochem Pharmacol. 80:561–567.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Solit DR, Garraway LA, Pratilas CA, et al:
BRAF mutation predicts sensitivity to MEK inhibition. Nature.
439:358–362. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Flaherty KT, Puzanov I, Kim KB, et al:
Inhibition of mutated activated Braf in metastatic melanoma. N Eng
J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Minami Y, Shimamura T, Shah K, et al: The
major lung cancer-derived mutants of ERBB2 are oncogenic and are
associated with sensitivity to the irreversible EGFR/ERBB2
inhibitor HKI-272. Oncogene. 26:5023–5027. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Greulich H, Chen TH, Feng W, et al:
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR
mutants. PLoS Med. 2:e2132005. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Sasaki H, Endo K, Takada M, et al: EGFR
exon20 insertion mutation in Japanese lung cancer. Lung Cancer.
58:324–328. 2007. View Article : Google Scholar : PubMed/NCBI
|
